Get the Stockscreener App
38.04
3.12%
1.15
Genmab Adr stock is traded at $38.04, with a volume of 2.81M.
It is up +3.12% in the last 24 hours and up +11.39% over the past month.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
See More
Previous Close:
$36.89
Open:
$37.2
24h Volume:
2.81M
Relative Volume:
0.55
Market Cap:
$23.39B
Revenue:
$3.91B
Net Income/Loss:
$823.88M
P/E Ratio:
28.68
EPS:
1.3262
Net Cash Flow:
$875.28M
1W Performance:
+5.52%
1M Performance:
+11.39%
6M Performance:
+29.83%
1Y Performance:
+16.26%
1-Day Range:
$37.04
$38.33
1-Week Range:
$36.12
$37.71
52-Week Range:
$23.62
$40.17
Genmab Adr Stock (GMAB) Company Profile
Compare GMAB vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
38.04 | 23.39B | 3.91B | 823.88M | 875.28M | 1.3262 |
VRTX
Vertex Pharmaceuticals Inc
|
510.21 | 129.32B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.15 | 95.08B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.82 | 82.55B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.38 | 53.54B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.08 | 42.09B | 5.76B | 514.49M | 1.10B | 4.4813 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-26 | Upgrade | TD Cowen | Hold → Buy |
| May-27-26 | Initiated | Truist | Buy |
| Apr-22-26 | Upgrade | Goldman | Neutral → Buy |
| Mar-27-26 | Initiated | Wolfe Research | Outperform |
| Mar-02-26 | Initiated | Wells Fargo | Overweight |
| Feb-17-26 | Resumed | Jefferies | Buy |
| Feb-17-26 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-23-25 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-01-25 | Downgrade | Bernstein | Mkt Perform → Underperform |
| Mar-11-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Feb-13-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-04-24 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-20-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-15-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-23-24 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-22-24 | Downgrade | Citigroup | Neutral → Sell |
| Dec-06-23 | Upgrade | UBS | Neutral → Buy |
| Nov-10-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Nov-08-23 | Upgrade | DNB Markets | Sell → Buy |
| Oct-18-23 | Initiated | Exane BNP Paribas | Underperform |
| Sep-06-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-24-23 | Initiated | BTIG Research | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-31-23 | Initiated | UBS | Neutral |
| May-12-23 | Initiated | Morgan Stanley | Underweight |
| Dec-20-22 | Downgrade | Citigroup | Buy → Neutral |
| Nov-14-22 | Initiated | William Blair | Mkt Perform |
| Nov-11-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-24-22 | Initiated | BMO Capital Markets | Market Perform |
| May-02-22 | Initiated | Cowen | Market Perform |
| Mar-16-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-01-21 | Initiated | Berenberg | Sell |
| Sep-16-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-24-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-20-21 | Initiated | Deutsche Bank | Buy |
| Jan-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-20 | Downgrade | Bryan Garnier | Neutral → Sell |
| Sep-08-20 | Initiated | SVB Leerink | Mkt Perform |
| Jun-25-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-23-20 | Initiated | Credit Suisse | Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-12-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Sep-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Sep-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | Morgan Stanley | Overweight |
| Aug-12-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Genmab Adr Stock (GMAB) Latest News
Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members - The Manila Times
AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL - Zacks Investment Research
Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength? - Zacks Investment Research
Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge - The Motley Fool
Genmab stock gains 5.32 percent on Rina-S data - AD HOC NEWS
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma - GlobeNewswire Inc.
Genmab stock after-hours at EUR 319.90: minus 0.03 percent versus the prior close at Lang & Schwarz - AD HOC NEWS
Genmab reports Rina-S results. Genmab stock falls 1.95 percent - AD HOC NEWS
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer - GlobeNewswire Inc.
Major Shareholder Announcement - GlobeNewswire Inc.
HC Wainwright keeps Buy on Genmab stock at USD 40 target - AD HOC NEWS
Genmab stock last trades at DKK 2,282.00 on September 28, 2026 - AD HOC NEWS
Genmab stock at DKK 2,277 on September 25, 2026, up 0.40 percent - AD HOC NEWS
Genmab stock gains 0.8 percent ahead of the open - AD HOC NEWS
Grant of Restricted Stock Units and Warrants to Employees in Genmab - GlobeNewswire Inc.
Genmab stock heads into the open after a 0.84 percent gain - AD HOC NEWS
Genmab stock gains as Kempen raises target to DKK 3,300 - AD HOC NEWS
Genmab stock heads into the open after a 10.80 percent year gain - AD HOC NEWS
Genmab stock advances as Q4 readouts stay on track - AD HOC NEWS
GMAB Q2 2026 Earnings: EPS Beats Consensus by 36.6% as Shares Edge HigherEarnings Analysis - www.dars.gov.et
GMAB Q2 2026 Earnings: EPS Beats Consensus by 36.6% as Shares Edge HigherEarnings Cycle Outlook - dars.gov.et
Genmab stock holds steady after first-half 2026 earnings update - AD HOC NEWS
Genmab stock gains as petosemtamab and Q2 figures draw focus - AD HOC NEWS
Genmab stock gains as petosemtamab Phase 3 start and strong Q2 figures support valuation - AD HOC NEWS
Genmab stock heads into the open after a modest gain - AD HOC NEWS
Genmab stock gains as HC Wainwright lifts Q3 earnings estimates and Phase 3 petosemtamab trial begin - AD HOC NEWS
Genmab stock gains as HC Wainwright lifts earnings estimates and confirms Buy rating - AD HOC NEWS
Genmab stock heads into the open after a 1.6% gain in Copenhagen - AD HOC NEWS
Coloplast stock edges lower despite strong quarterly profit surge - AD HOC NEWS
Genmab stock gains as capital increase and updated Articles of Association support growth plans - AD HOC NEWS
Genmab stock gains support as Barclays lifts target after warrant-driven share issue - AD HOC NEWS
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
symbol__ Stock Quote Price and Forecast - CNN
Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewswire Inc.
Notice to Convene an Extraordinary General Meeting of Genmab A/S - The Manila Times
ETFs Investing in Genmab A/S Sponsored ADR Stocks - TradingView
Genmab stock holds steady as analysts stick to a moderate buy view - AD HOC NEWS
Genmab A/S ADSADR Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Genmab (GMAB) Q2 2026 Earnings: EPS Surges 36.6% Past EstimatesCost Structure Review - careplusvn.com
Genmab (GMAB) Q2 2026 Earnings: EPS Surges 36.6% Past EstimatesGAAP Earnings Report - dars.gov.et
Genmab stock holds steady as investors await next data catalysts - AD HOC NEWS
Genmab A/S (GMAB) Slips 0.21% to $33.16 Amid Range-Bound TradingPCR Mean Reversion - dars.gov.et
Genmab A/S (GMAB) Slips 0.21% to $33.16 Amid Range-Bound TradingMarket Cap Weight - dars.gov.et
Genmab A/S (GMAB) Slips 0.21% to $33.16 Amid Range-Bound TradingValue Stock Ideas - dars.gov.et
Genmab A/S (GMAB) Slips 0.21% to $33.16 Amid Range-Bound TradingWave Truncation - dars.gov.et
Genmab A/S (GMAB) Slips 0.21% to $33.16 Amid Range-Bound TradingLow Vol Factor - dars.gov.et
Genmab stock holds in the mid-$30s as higher 2026 guidance leans on royalty income - ad-hoc-news.de
Genmab A/S ADSADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Genmab stock steadies as 2026 royalty-driven guidance lifts revenue outlook - AD HOC NEWS
Genmab A/S ADSADR Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Genmab Adr Stock (GMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Genmab Adr Stock (GMAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GENMAB A/S | 10% Owner |
Dec 26 '25 |
Buy |
97.00 |
2,978 |
288,866 |
72,831,487 |
| GENMAB A/S | 10% Owner |
Dec 26 '25 |
Buy |
97.00 |
142,610 |
13,833,170 |
72,828,509 |
| GENMAB A/S | 10% Owner |
Dec 24 '25 |
Buy |
97.00 |
96,082 |
9,319,954 |
72,685,899 |
| GENMAB A/S | 10% Owner |
Dec 23 '25 |
Buy |
97.00 |
561,042 |
54,421,074 |
72,589,817 |
| GENMAB A/S | 10% Owner |
Dec 22 '25 |
Buy |
97.00 |
15,710 |
1,523,870 |
72,028,775 |
| GENMAB A/S | 10% Owner |
Dec 19 '25 |
Buy |
97.00 |
66,264 |
6,427,608 |
72,013,065 |
| GENMAB A/S | 10% Owner |
Dec 18 '25 |
Buy |
97.00 |
212,177 |
20,581,169 |
71,946,801 |
| GENMAB A/S | 10% Owner |
Dec 17 '25 |
Buy |
97.00 |
150,795 |
14,627,115 |
71,734,624 |
| GENMAB A/S | 10% Owner |
Dec 16 '25 |
Buy |
97.00 |
120,752 |
11,712,944 |
71,583,829 |
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):